Screener
Dianthus Therapeutics DNTH Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeInterestAndDividend.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Total operating expenses | 46,996 | 34,340 |
| Loss from operations | (46,533) | (33,177) |
| Other income/(expense): | ||
| Interest and investment income | 6,265 | 3,791 |
| Loss on investment in former related party | (302) | (5) |
| Loss on currency exchange, net | (15) | (22) |
| Other expense | (249) | (98) |
| Total other income | 5,699 | 3,666 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's interest income?
- Dianthus Therapeutics (DNTH) reported interest income of $6.27M in Q1 2026.
- How has Dianthus Therapeutics's interest income changed year-over-year?
- Dianthus Therapeutics's interest income increased by 65.3% year-over-year, from $3.79M to $6.27M.
- What is the long-term trend for Dianthus Therapeutics's interest income?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's interest income has grown at a 69.7% compound annual growth rate (CAGR), from $3.56M to $17.37M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Dianthus Therapeutics's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude